Use of biomarkers in pediatric sepsis: literature review

Vanessa Soares Lanziotti, Pedro Póvoa, Márcio Soares, José Roberto Lapa E Silva, Arnaldo Prata Barbosa, Jorge Ibrain Figueira Salluh, Vanessa Soares Lanziotti, Pedro Póvoa, Márcio Soares, José Roberto Lapa E Silva, Arnaldo Prata Barbosa, Jorge Ibrain Figueira Salluh

Abstract

Despite advances in recent years, sepsis is still a leading cause of hospitalization and mortality in infants and children. The presence of biomarkers during the response to an infectious insult makes it possible to use such biomarkers in screening, diagnosis, prognosis (risk stratification), monitoring of therapeutic response, and rational use of antibiotics (for example, the determination of adequate treatment length). Studies of biomarkers in sepsis in children are still relatively scarce. This review addresses the use of biomarkers in sepsis in pediatric patients with emphasis on C-reactive protein, procalcitonin, interleukins 6, 8, and 18, human neutrophil gelatinase, and proadrenomedullin. Assessment of these biomarkers may be useful in the management of pediatric sepsis.

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Biomarkers in pediatric sepsis. CRP - C-reactive protein; PCT - procalcitonin; IL-6 - interleukin 6; IL-8 - interleukin 8; NGAL - human neutrophil gelatinase.

References

    1. Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, Singhi SC, Erickson S, Roy JA, Bush JL, Nadkarni VM, Thomas NJ, Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators. Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147–1157. Erratum in Global Epidemiology of Pediatric Severe Sepsis: The Sepsis Prevalence, Outcomes, and Therapies Study. [Am J Respir Crit Care Med. 2016]
    1. Ruth A, McCracken CE, Fortenberry JD, Hall M, Simon HK, Hebbar KB. Pediatric severe sepsis: current trends and outcomes from the Pediatric Health Information Systems database. Pediatr Crit Care Med. 2014;15(9):828–838.
    1. Goldstein B, Giroir B, Randolph A, International Consensus Conference on Pediatric Sepsis International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2–8. Review.
    1. Kissoon N, Carcillo JA, Espinosa V, Argent A, Devictor D, Madden M, Singhi S, van der Voort E, Latour J, Global Sepsis Initiative Vanguard Center Contributors World Federation of Pediatric Intensive Care and Critical Care Societies: Global Sepsis Initiative. Pediatr Crit Care Med. 2011;12(5):494–503.
    1. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.
    1. Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med. 2005;6(3) Suppl:S55–S60.
    1. Rabello LS, Rosolem MM, Leal JV, Soares M, Lisboa T, Salluh JI. Entendendo o conceito PIRO: da teoria à prática clínica - Parte 1. Rev Bras Ter Intensiva. 2009;21(4):425–431.
    1. Marshall JC, Reinhart K, International Sepsis Forum Biomarkers of sepsis. Crit Care Med. 2009;37(7):2290–2298. Review.
    1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
    1. Salluh JI, Bozza PT. Biomarkers of sepsis: lost in translation? Crit Care Med. 2008;36(7):2192–2194.
    1. Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011;12(2):165–173.
    1. McWilliam S, Riordan A. How to use: C-reactive protein. Arch Dis Child Educ Pract Ed. 2010;95(2):55–58.
    1. Sanders S, Barnett A, Correa-Velez I, Coulthard M, Doust J. Systematic review of the diagnostic accuracy of C-reactive protein to detect bacterial infection in nonhospitalized infants and children with fever. J Pediatr. 2008;153(4):570–574.
    1. Hengst JM. The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care. 2003;3(1):3–13. Review.
    1. Patil S, Dutta S, Attri SV, Ray P, Kumar P. Arch Dis Child Fetal Neonatal Ed. Apr 29, 2016. Serial C reactive protein values predict sensitivity of organisms to empirical antibiotics in neonates: a nested case-control study. [Epub ahead of print]
    1. Santolaya ME, Alvarez AM, Avilés CL, Becker A, Venegas M, O'Ryan M, et al. Prospective validation of a risk prediction model for severe sepsis in children with cancer and high-risk febrile neutropenia. Pediatr Infect Dis J. 2013;32(12):1318–1323.
    1. Kitanovski L, Jazbec J, Hojker S, Derganc M. Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer. 2014;22(1):269–277.
    1. Póvoa P, Salluh JI. Use of biomarkers in sepsis: many questions, few answers. Rev Bras Ter Intensiva. 2013;25(1):1–2.
    1. Póvoa P, Teixeira-Pinto AM, Carneiro AH, Portuguese Community-Acquired Sepsis Study Group SACiUCI C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care. 2011;15(4):R169–R169.
    1. Coelho LM, Salluh JI, Soares M, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, et al. Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study. Crit Care. 2012;16(2):R53–R53.
    1. Lanziotti VS, Póvoa P, Pulcheri L, Meirelles PZ, Guimarães G, Mendes AS, et al. C-reactive protein ratio response patterns in pediatric sepsis: a cohort study - preliminary results. Intensive Care Med Exp. 2015;3(Suppl 1):A787–A787.
    1. Salluh JI, Lisboa T. C-reactive protein in community-acquired sepsis: you can teach new tricks to an old dog. Crit Care. 2011;15(5):186–186.
    1. Salluh JI, Nobre V, Povoa P. Using procalcitonin to guide antimicrobial duration in sepsis: asking the same questions will not bring different answers. Crit Care. 2014;18(3):142–142.
    1. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426–435.
    1. Pierce R, Bigham MT, Giuliano Jr JS. Use of procalcitonin for the prediction and treatment of acute bacterial infection in children. Curr Opin Pediatr. 2014;26(3):292–298. Review.
    1. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther. 2010;8(5):575–587.
    1. Rey C, Los Arcos M, Concha A, Medina A, Prieto S, Martinez P, et al. Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children. Intensive Care Med. 2007;33(3):477–484.
    1. Fioretto JR, Martin JG, Kurokawa CS, Carpi MF, Bonatto RC, de Moraes MA, et al. Comparison between procalcitonin and C-reactive protein for early diagnosis of children with sepsis and septic shock. Inflamm Res. 2010;59(8):581–586.
    1. England JT, Del Vecchio MT, Aronoff SC. Use of serum procalcitonin in evaluation of febrile infants: a meta-analysis of 2317 patients. J Emerg Med. 2014;47(6):682–688.
    1. Arkader R, Troster EJ, Lopes MR, Júnior RR, Carcillo JA, Leone C, et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child. 2006;91(2):117–120.
    1. Han YY, Doughty LA, Kofos D, Sasser H, Carcillo JA. Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med. 2003;4(1):21–25.
    1. Li Z, Wang H, Liu J, Chen B, Li G. Serum soluble triggering receptor expressed on myeloid cells-1 and procalcitonin can reflect sepsis severity and predict prognosis: a prospective cohort study. Mediators Inflamm. 2014;2014:641039–641039.
    1. Fioretto JR, Borin FC, Bonatto RC, Ricchetti SM, Kurokawa CS, de Moraes M, et al. Procalcitonin in children with sepsis and septic shock. J Pediatr (Rio J) 2007;83(4):323–328.
    1. Hu R, Gong Y, Wang Y. Relationship of serum procalcitonin levels to severity and prognosis in pediatric bacterial meningitis. Clin Pediatr (Phila) 2015;54(12):1141–1144.
    1. Henry BM, Roy J, Ramakrishnan PK, Vikse J, Tomaszewski KA, Walocha JA. Procalcitonin as a serum biomarker for differentiation of bacterial meningitis from viral meningitis in children: evidence from a meta-analysis. Clin Pediatr (Phila) 2016;55(8):749–764.
    1. Zhang H, Yang J, Lin L, Huo B, Dai H, He Y. Diagnostic value of serum procalcitonin for acute pyelonephritis in infants and children with urinary tract infections: an updated meta-analysis. World J Urol. 2016;34(3):431–441.
    1. Hatzistilianou M, Rekliti A, Athanassiadou F, Catriu D. Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. Inflamm Res. 2010;59(5):339–347.
    1. Reyna-Figueroa J, Lagunas-Martínez A, Martínez Matsumoto P, Madrid-Marina V. Procalcitonin as a diagnostic biomarker of sepsis in children with cancer, fever and neutropenia: literature review. Arch Argent Pediatr. 2015;113(1):46–52. Spanish.
    1. Arkader R, Troster EJ, Abellan DM, Lopes MR, Júnior RR, Carcillo JA, et al. Procalcitonin and C-reactive protein kinetics in postoperative pediatric cardiac surgical patients. J Cardiothorac Vasc Anesth. 2004;18(2):160–165.
    1. McMaster P, Park DY, Shann F, Cochrane A, Morris K, Gray J, et al. Procalcitonin versus C-reactive protein and immature-to-total neutrophil ratio as markers of infection after cardiopulmonary bypass in children. Pediatr Crit Care Med. 2009;10(2):217–221.
    1. Mann EA, Wood GL, Wade CE. Use of procalcitonin for the detection of sepsis in the critically ill burn patient: a systematic review of the literature. Burns. 2011;37(4):549–558.
    1. Rosanova MT, Tramonti N, Taicz M, Martiren S, Basílico H, Signorelli C, et al. Assessment of C-reactive protein and procalcitonin levels to predict infection and mortality in burn children. Arch Argent Pediatr. 2015;113(1):36–41.
    1. Zurek J, Vavrina M. Procalcitonin biomarker kinetics to predict multiorgan dysfunction syndrome in children with sepsis and systemic inflammatory response syndrome. Iran J Pediatr. 2015;25(1):e324.
    1. Huang SY, Tang RB, Chen SJ, Chung RL. Serum interleukin-6 level as a diagnostic test in children with sepsis. J Chin Med Assoc. 2003;66(9):523–527.
    1. Pavare J, Grope I, Kalnins I, Gardovska D. High-mobility group box-1 protein, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in children with community acquired infections and bacteraemia: a prospective study. BMC Infect Dis. 2010;10:28–28.
    1. Wong HR, Shanley TP, Sakthivel B, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, Penfil S, Monaco M, Tagavilla MA, Odoms K, Dunsmore K, Barnes M, Aronow BJ, Genomics of Pediatric SIRS/Septic Shock Investigators Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics. 2007;30(2):146–155.
    1. Wong HR, Cvijanovich N, Wheeler DS, Bigham MT, Monaco M, Odoms K, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med. 2008;178(3):276–282.
    1. Cost CR, Stegner MM, Leonard D, Leavey P. IL-8 predicts pediatric oncology patients with febrile neutropenia at low risk for bacteremia. J Pediatr Hematol Oncol. 2013;35(3):206–211.
    1. Santolaya ME, Alvarez AM, Avilés CL, Becker A, Venegas M, O'Ryan M, et al. Prospective validation of a risk prediction model for severe sepsis in children with cancer and high-risk febrile neutropenia. Pediatr Infect Dis J. 2013;32(12):1318–1323.
    1. Calfee CS, Thompson BT, Parsons PE, Ware LB, Matthay MA, Wong HR. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Crit Care Med. 2010;38(6):1436–1441.
    1. Grobmyer SR, Lin E, Lowry SF, Rivadeneira DE, Potter S, Barie PS, et al. Elevation of IL-18 in human sepsis. J Clin Immunol. 2000;20(3):212–215.
    1. Cusumano V, Midiri A, Cusumano VV, Bellantoni A, De Sossi G, Teti G, et al. Interleukin-18 is an essential element in host resistance to experimental group B streptococcal disease in neonates. Infect Immun. 2004;72(1):295–300.
    1. Tschoeke SK, Oberholzer A, Moldawer LL. Interleukin-18: a novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med. 2006;34(4):1225–1233.
    1. Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care. 2007;11(4):R84–R84.
    1. Ronco C. N-GAL: diagnosing AKI as soon as possible. Crit Care. 2007;11(6):173–173.
    1. Wheeler DS, Devarajan P, Ma Q, Harmon K, Monaco M, Cvijanovich N, et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med. 2008;36(4):1297–1303.
    1. Di Nardo M, Ficarella A, Ricci Z, Luciano R, Stoppa F, Picardo S, et al. Impact of severe sepsis on serum and urinary biomarkers of acute kidney injury in critically ill children: an observational study. Blood Purif. 2013;35(1-3):172–176.
    1. Kim H, Hur M, Cruz DN, Moon HW, Yun YM. Plasma neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Clin Biochem. 2013;46(15):1414–1418.
    1. Linscheid P, Seboek D, Zulewski H, Keller U, Mülller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology. 2005;146(6):2699–2708.
    1. Hirata Y, Mitaka C, Sato K, Nagura T, Tsonuda Y, Amaha K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide in sepsis. J Clin Endocrinol Metab. 1996;81(4):1449–1453.
    1. Jordan I, Corniero P, Balaguer M, Ortiz J, Vila D, Velasco J, et al. Adrenomedullin is a useful biomarker for the prognosis of critically ill septic children. Biomark Med. 2014;8(9):1065–1072.
    1. Demirkaya M, Tugcu D, Akcay A, Aydogan G, Akici F, Salcioglu Z, et al. Adrenomedullin--A new marker in febrile neutropenia: comparison with CRP and procalcitonin. Pediatr Hematol Oncol. 2015;32(7):482–489.
    1. Christ-Crain M, Morgenthaler NG, Stolz D, Müller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397] Crit Care. 2006;10(3):R96–R96.
    1. Rabello LS, Pitrowsky MT, Soares M, Póvoa P, Salluh JI. Novel biomarkers in severe community-acquired pneumonia. Rev Bras Ter Intensiva. 2011;23(4):499–506.
    1. Wong HR, Salisbury S, Xiao Q, Cvijanovich NZ, Hall M, Allen GL, et al. The pediatric sepsis biomarker risk model. Crit Care. 2012;16(5):R174–R174.
    1. Wong HR, Weiss SL, Giuliano Jr JS, Wainwright MS, Cvijanovich NZ, Thomas NJ, et al. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS One. 2014;9(1):e86242.
    1. Wang K, Bhandari V, Giuliano Jr JS, O Hern CS, Shattuck MD, Kirby M. Angiopoietin-1, angiopoietin-2 and bicarbonate as diagnostic biomarkers in children with severe sepsis. PLoS One. 2014;9(9):e108461.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj